Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3520 ARTÍCULOS , VIENDO DEL 1486 AL 1500

Malignant melanoma, breast cancer and other cancers in patients with Parkinson's disease

Rugbjerg K, Friis S, Lassen CF, Ritz B, Olsen JH.

Int J Cancer. 2012 Oct 15;131(8):1904-11. doi: 10.1002/ijc.27443. Epub 2012 Mar 22.

[Psychosis in Parkinson's disease]

Rongve A, Auning E, Ehrt U, Arsland D.

Tidsskr Nor Laegeforen. 2012 Jan 24;132(2):155-8. doi: 10.4045/tidsskr.11.0723.

Assessment of cognitive fluctuation in dementia: a systematic review of the literature

Lee DR, Taylor JP, Thomas AJ.

Int J Geriatr Psychiatry. 2012 Oct;27(10):989-98. doi: 10.1002/gps.2823. Epub 2012 Jan 25.

Virtual reality as a tool for evaluation of repetitive rhythmic movements in the elderly and Parkinson's disease patients

Arias P, Robles-García V, Sanmartín G, Flores J, Cudeiro J.

PLoS One. 2012;7(1):e30021. doi: 10.1371/journal.pone.0030021. Epub 2012 Jan 18.

[Autonomic nervous system as a source of biomarkers in Parkinson's disease]

Pouclet H, Lebouvier T, Flamant M, Coron E, Neunlist M, Derkinderen P, Rouaud T.

Presse Med. 2012 Jul;41(7-8):695-701. doi: 10.1016/j.lpm.2011.11.018. Epub 2012 Jan 28.

Effects of zonisamide on tardive dyskinesia: a preliminary open-label trial

Iwata Y, Irie S, Uchida H, Suzuki T, Watanabe K, Iwashita S, Mimura M.

J Neurol Sci. 2012 Apr 15;315(1-2):137-40. doi: 10.1016/j.jns.2011.12.010. Epub 2012 Jan 28.

The development of encapsulated cell technologies as therapies for neurological and sensory diseases

Zanin MP, Pettingill LN, Harvey AR, Emerich DF, Thanos CG, Shepherd RK.

J Control Release. 2012 May 30;160(1):3-13. doi: 10.1016/j.jconrel.2012.01.021. Epub 2012 Jan 21.

Turning and unilateral cueing in Parkinson's disease patients with and without freezing of gait

Spildooren J, Vercruysse S, Meyns P, Vandenbossche J, Heremans E, Desloovere K, Vandenberghe W, Nieuwboer A.

Neuroscience. 2012 Apr 5;207:298-306. doi: 10.1016/j.neuroscience.2012.01.024. Epub 2012 Jan 18.

(R)-2-[(11)C]Methoxy-N-n-propylnorapomorphine

Leung K.

2006 Apr 11 [updated 2012 Feb 1]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013.

Drosophila models of proteinopathies: the little fly that could

Rincon-Limas DE, Jensen K, Fernandez-Funez P.

Curr Pharm Des. 2012;18(8):1108-22. doi: 10.2174/138161212799315894.

No clinically significant valvular regurgitation in long-term cabergoline treatment for prolactinoma

Halperin I, Aller J, Varela C, Mora M, Abad A, Doltra A, Santos AE, Batista E, García-Pavía P, Sitges M, Mirelis JG, Lucas T, Puig-Domingo M.

Clin Endocrinol (Oxf). 2012 Aug;77(2):275-80. doi: 10.1111/j.1365-2265.2012.04349.x.

Translation and validation of the Swedish version of the mini-BESTest in subjects with Parkinson's disease or stroke: a pilot study

Bergström M, Lenholm E, Franzén E.

Physiother Theory Pract. 2012 Oct;28(7):509-14. doi: 10.3109/09593985.2011.653707. Epub 2012 Jan 30.

The six gaps in the search of neuroprotection for Parkinson's disease

Espay AJ, Fasano A, Morgante F.

Expert Rev Neurother. 2012 Feb;12(2):111-3. doi: 10.1586/ern.11.202.

Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone

Reichmann H, Emre M.

Expert Rev Neurother. 2012 Feb;12(2):119-31. doi: 10.1586/ern.11.203.

IPX066: a novel carbidopa-levodopa extended-release formulation

Hauser RA.

Expert Rev Neurother. 2012 Feb;12(2):133-40. doi: 10.1586/ern.11.195.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias